PPARGC1A and Huntington disease: Transcriptional repression of PGC-1α by mutant huntingtin resulting in mitochondrial abnormality and neurodegeneration has also been shown in a HD mouse model, suggesting that agents enhancing the transcriptional activity of PGC-1α may be potential therapeutics for HD [23,24].